JP2021514667A5 - - Google Patents

Info

Publication number
JP2021514667A5
JP2021514667A5 JP2020547085A JP2020547085A JP2021514667A5 JP 2021514667 A5 JP2021514667 A5 JP 2021514667A5 JP 2020547085 A JP2020547085 A JP 2020547085A JP 2020547085 A JP2020547085 A JP 2020547085A JP 2021514667 A5 JP2021514667 A5 JP 2021514667A5
Authority
JP
Japan
Prior art keywords
peptide
hpv
seq
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020547085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514667A (ja
JP7581048B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020933 external-priority patent/WO2019173465A1/en
Publication of JP2021514667A publication Critical patent/JP2021514667A/ja
Priority to JP2023103636A priority Critical patent/JP7885176B2/ja
Publication of JP2021514667A5 publication Critical patent/JP2021514667A5/ja
Application granted granted Critical
Publication of JP7581048B2 publication Critical patent/JP7581048B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020547085A 2018-03-06 2019-03-06 ヒトパピローマウイルスワクチンおよびその使用 Active JP7581048B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023103636A JP7885176B2 (ja) 2018-03-06 2023-06-23 ヒトパピローマウイルスワクチンおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639354P 2018-03-06 2018-03-06
US62/639,354 2018-03-06
PCT/US2019/020933 WO2019173465A1 (en) 2018-03-06 2019-03-06 Human papillomavirus vaccines and uses of the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023103636A Division JP7885176B2 (ja) 2018-03-06 2023-06-23 ヒトパピローマウイルスワクチンおよびその使用

Publications (3)

Publication Number Publication Date
JP2021514667A JP2021514667A (ja) 2021-06-17
JP2021514667A5 true JP2021514667A5 (cg-RX-API-DMAC7.html) 2024-01-15
JP7581048B2 JP7581048B2 (ja) 2024-11-12

Family

ID=78414121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020547085A Active JP7581048B2 (ja) 2018-03-06 2019-03-06 ヒトパピローマウイルスワクチンおよびその使用
JP2023103636A Active JP7885176B2 (ja) 2018-03-06 2023-06-23 ヒトパピローマウイルスワクチンおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023103636A Active JP7885176B2 (ja) 2018-03-06 2023-06-23 ヒトパピローマウイルスワクチンおよびその使用

Country Status (11)

Country Link
US (2) US12404306B2 (cg-RX-API-DMAC7.html)
EP (1) EP3762022A4 (cg-RX-API-DMAC7.html)
JP (2) JP7581048B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200130339A (cg-RX-API-DMAC7.html)
CN (1) CN112088015A (cg-RX-API-DMAC7.html)
AU (1) AU2019231654B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092937A1 (cg-RX-API-DMAC7.html)
IL (2) IL314393A (cg-RX-API-DMAC7.html)
SG (1) SG11202008539YA (cg-RX-API-DMAC7.html)
WO (1) WO2019173465A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202005673B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111868074A (zh) * 2018-01-24 2020-10-30 昆士兰医学研究所理事会 Hpv免疫疗法
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
SG11202008539YA (en) 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
CA3197920A1 (en) * 2020-11-25 2022-06-02 Douglas E. Brough Human papilloma virus vaccines and uses of the same for hpv associated diseases
JP2026518240A (ja) * 2023-05-22 2026-06-04 プレシゲン,インコーポレイテッド 再発性呼吸器乳頭腫症の処置のための新規アデノウイルスワクチン療法
AU2024274630A1 (en) * 2023-05-22 2026-01-22 Precigen, Inc. Human papillomavirus vaccines and uses of the same

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
FR2593630B1 (fr) 1986-01-27 1988-03-18 Maurice Francois Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
AU655417B2 (en) 1990-03-22 1994-12-22 Salk Institute For Biological Studies, The Insect retinoid receptor compositions and methods
CA2043775A1 (en) 1990-06-14 1991-12-15 Dat P. Le Dibenzoylakylcyanohydrazines
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE69634630T2 (de) 1995-03-03 2005-11-10 Syngenta Participations Ag Kontrolle der pflanzengenexpression durch rezeptor-vermittelte transaktivation in gegenwart von einem chemischen ligand
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6001622A (en) 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
DK0973928T3 (da) 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
AU738494B2 (en) 1997-07-10 2001-09-20 Salk Institute For Biological Studies, The Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
WO2001030965A2 (en) 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
WO2001051528A1 (en) 2000-01-12 2001-07-19 Eastman Chemical Company Procatalysts comprising bidentate ligands, catalyst systems, and use in olefin polymerization
WO2001070816A2 (en) 2000-03-22 2001-09-27 Rohm And Haas Company Ecdysone receptor-based inducible gene expression system
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
ATE320493T1 (de) 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
CA2438119C (en) 2001-02-20 2014-12-16 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
ES2385598T3 (es) 2001-02-20 2012-07-27 Intrexon Corporation Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
EP1534738B1 (en) 2001-02-20 2012-06-20 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
AU2002306550B2 (en) 2001-02-20 2007-10-25 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
WO2003020879A2 (en) 2001-07-23 2003-03-13 Genvec, Inc. Cells and methods for propagating adenoviral vectors
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
EP1425045A4 (en) 2001-09-13 2004-11-10 Genvec Inc ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP2005532781A (ja) 2001-09-26 2005-11-04 レオジーン・ホールディングス,インコーポレーテッド ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用
EP1490686A2 (en) 2001-09-26 2004-12-29 RheoGene Holdings Inc. Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
WO2008051854A2 (en) 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
MX363066B (es) 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
GB0710538D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
JP2010539993A (ja) 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
MX340972B (es) 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
EP2550359B1 (en) 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
EP2681327B1 (en) 2011-03-04 2018-11-21 Intrexon Corporation Vectors conditionally expressing protein
KR102067760B1 (ko) 2011-08-16 2020-01-17 삼성전자주식회사 세포 내 전달용 단백질 복합체 및 그의 용도
BR112014008167B1 (pt) 2011-10-05 2022-05-24 Genvec Inc Adenovírus ou vetor adenoviral e composição os compreendendo
CA2851251C (en) 2011-10-05 2023-09-12 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
CA2850627C (en) 2011-10-05 2024-05-21 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
WO2013053008A2 (en) 2011-10-14 2013-04-18 The Walter And Eliza Hall Institute Of Medical Research Molecules which bind clec9a
CN104159607A (zh) 2012-01-24 2014-11-19 桑福德研究院/南达科他大学 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
EP2855511B1 (en) * 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine
SG11201604781RA (en) 2013-12-18 2016-07-28 Intrexon Corp Single chain il-12 nucleic acids, polypeptids, and uses thereof
WO2015106281A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CN107073070A (zh) 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
SG11201702295UA (en) 2014-09-22 2017-04-27 Intrexon Corp Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
JP6775515B2 (ja) 2015-03-11 2020-10-28 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム トランスポザーゼポリペプチド及びその使用
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
CA3001351A1 (en) 2015-10-21 2017-04-27 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hepatitis b virus
WO2017083750A1 (en) 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
CA3012829A1 (en) * 2016-01-27 2017-08-03 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
JP2019517522A (ja) * 2016-06-03 2019-06-24 エトゥビクス コーポレーション ヒトパピローマウイルス(hpv)関連疾患の処置のための組成物及び方法
SG11202008539YA (en) 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same

Similar Documents

Publication Publication Date Title
Gershon et al. Early transcription factor subunits are encoded by vaccinia virus late genes.
JP2025004002A5 (cg-RX-API-DMAC7.html)
JP2023138959A5 (cg-RX-API-DMAC7.html)
JP2007513634A5 (cg-RX-API-DMAC7.html)
HRP20250701T1 (hr) Himerni protein papiloma virusa l1
Senkevich et al. Vaccinia virus E10R protein is associated with the membranes of intracellular mature virions and has a role in morphogenesis
JP2022062113A5 (cg-RX-API-DMAC7.html)
JP2012152218A5 (cg-RX-API-DMAC7.html)
JP2002510494A5 (cg-RX-API-DMAC7.html)
CN106831961A (zh) 一种人乳头瘤病毒58型l1蛋白的突变体
JP2020517260A5 (cg-RX-API-DMAC7.html)
RU2015148190A (ru) Слитые полипептиды и вакцины
CN106831959B (zh) 一种人乳头瘤病毒33型l1蛋白的突变体
JP2022070902A5 (cg-RX-API-DMAC7.html)
KR102878566B1 (ko) 인간 유두종바이러스용 다가 면역원성 조성물
CN104387473B (zh) 用于非酶切非色谱纯化方法原核表达融合蛋白Prx的类弹性蛋白多肽ELP
JP2023550480A5 (cg-RX-API-DMAC7.html)
JP2015524420A5 (cg-RX-API-DMAC7.html)
KR102301136B1 (ko) 글루카곤 유사 펩타이드-1 또는 이의 유사체 생산용 융합태그
JP2022505094A5 (cg-RX-API-DMAC7.html)
RU2015100212A (ru) Химерные белки на основе hpv/cyaa и их применение в индукции имунного ответа против hpv-инфекции и расстройств, вызываемых hpv
JP2023532415A5 (cg-RX-API-DMAC7.html)
Atsushi et al. Homologies between herpesvirus of turkey and Marek's disease virus type-1 DNAs within two co-linearly arranged open reading frames, one encoding glycoprotein A
KR100492820B1 (ko) 돼지 유행성 설사병 바이러스 중화 에피토프 및 이의 이용
KR20140135716A (ko) 1→2 해독 프레임 이동의 감소 방법